RTI Surgical
Global surgical implant company using additive manufacturing to produce Fortilink spinal interbody devices with porous architectures for bone fusion.
- CEO / Founder
- Camille Farhat
- Team Size
- 1001-5000
- Stage
- Acquired
- Total Funding
- $79.8M
- Latest Round
- Acquired
Technology & Products
Key Products
Fortilink spinal interbody systems; Tetrafuse 3D technology; Biologic, metal, and synthetic implants
Technological Advantage
RTI's Fortilink family is produced by additive manufacturing, allowing porous structures that promote bone ingrowth. The Tetrafuse technology is protected by patents and FDA clearances, providing a regulatory barrier to entry.
Differentiation
Value Proposition
3D-printed porous PEEK/titanium spinal implants promote bone ingrowth and fusion, reducing revision rates and improving patient outcomes while enabling faster product innovation.
How They Differentiate
RTI differentiates through its Tetrafuse 3D-printed PEEK technology, which combines the osteoconductive properties of porous titanium with the favorable modulus of PEEK, while competitors focus on titanium-only 3D-printed interbodies.
Market & Competition
Target Customers
Spine surgeons, hospitals, and medical device distributors
Industry Verticals
Medical devices; Spine surgery; Orthopedics
Competitors
Zimmer Biomet (EIT Emerging Implant Technologies); Stryker (Tritanium); Alphatec Holdings
Growth & Milestones
Growth Metrics
Q2 2019 revenue grew 16.4% YoY to $82.31M; full-year 2019 revenue preliminarily reported in January 2020.
Major Milestones
1998: Founded as Regeneration Technologies, Inc.; 2017: Camille Farhat named CEO; 2020: Sold OEM business to Montagu Private Equity for $490M; renamed Surgalign Holdings; 2023: Surgalign filed for Chapter 11 and was acquired by Xtant Medical